ORPHA:506
Leigh syndrome
Also known as: Infantile subacute necrotizing encephalopathy · Leigh disease
Publications
6,446
Trials
15
Interventional, condition-specific
Researchers
1,501
Distinct authors in sample
Gene link
ADAR, AIFM1, ATP5MK
Definitive
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A neurological disease defined by specific neuropathological features associating brainstem and basal ganglia lesions.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0009723
- MeSH:D007888
- OMIM:256000
- UMLS:C2931891
- NCIT:C84814
Additional Mondo synonyms (5)
LS · LSS · Leigh syndrome spectrum · Leigh's disease · infantile subacute necrotizing encephalopathy
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedPresent
Definitive — ADAR, AIFM1, ATP5MK, BCS1L, BTD…
- LiteraturePresent
6,446 matched papers (3,790 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPresent
15 matched on ClinicalTrials.gov (4 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (ADAR, AIFM1, ATP5MK…).
GenCC classification: Definitive.
- ADAR
- AIFM1
- ATP5MK
- BCS1L
- BTD
- CLPB
- COQ9
- COX10
- COX15
- COX4I1
- COX8A
- COXFA4
- DLAT
- DLD
- DNM1L
- EARS2
- ECHS1
- ETHE1
- FARS2
- FBXL4
- FOXRED1
- GFM1
- GFM2
- GTPBP3
- HIBCH
- HPDL
- IARS2
- KGD4
- LIAS
- LIPT1
- LONP1
- LRPPRC
- MECR
- MFF
- MORC2
- MRPS34
- MT-ATP6
- MT-CO1
- MT-CO2
- MT-CO3
- MT-ND1
- MT-ND2
- MT-ND3
- MT-ND4
- MT-ND5
- MT-ND6
- MT-TI
- MT-TK
- MT-TL1
- MT-TL2
- MT-TV
- MT-TW
- MTFMT
- MTRFR
- NARS2
- NAXE
- NDUFA1
- NDUFA10
- NDUFA12
- NDUFA13
- NDUFA2
- NDUFA3
- NDUFA9
- NDUFAF2
- NDUFAF4
- NDUFAF5
- NDUFAF6
- NDUFAF8
- NDUFB8
- NDUFC2
- NDUFS1
- NDUFS2
- NDUFS3
- NDUFS4
- NDUFS7
- NDUFS8
- NDUFV1
- NDUFV2
- NUBPL
- NUP62
- OPA1
- PDHA1
- PDHB
- PDHX
- PDSS2
- PET100
- PET117
- PNPT1
- POLG
- PTCD3
- RANBP2
- RNASEH1
- SCO2
- SDHA
- SDHAF1
- SERAC1
- SLC19A3
- SLC25A19
- SLC25A4
- SLC25A46
- SLC39A8
- SQOR
- SSBP1
- SUCLA2
- SUCLG1
- SURF1
- TACO1
- TARS2
- TIMMDC1
- TPK1
- TRMU
- TSFM
- TTC19
- UQCRQ
- VPS13D
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
6,446
6,446 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
6,446 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
3,790 in the last 10 years · low confidence
Phrase hits: 6,446 · MeSH hits: 0
Who's working on it?
1,501
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Murayama K10 papers · 2026
Department of Metabolism, Chiba Children's Hospital, Japan.
Papers in Europe PMC - 02Rahman S10 papers · 2025
Genetics and Genomic Medicine Department, UCL Great Ormond Street Institute of Child Health, London, United Kingdom; Metabolic Medicine Department, Great Ormond Street Hospital for Children, London, United Kingdom. Electronic address: shamima.rahman@ucl.ac.uk.
Papers in Europe PMC - 03Fang F8 papers · 2026
Department of Neurology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Papers in Europe PMC - 04
- 05Falk MJ7 papers · 2025
Mitochondrial Medicine Frontier Program, Division of Human Genetics, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Papers in Europe PMC - 06Johnson SC7 papers · 2026
Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Papers in Europe PMC - 07Chen Y6 papers · 2026
Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Papers in Europe PMC - 08Ohtake A6 papers · 2026
Department of Clinical Genomics, Faculty of Medicine, Saitama Medical University, Moroyama 350-0495, Japan.
Papers in Europe PMC - 09James K5 papers · 2026
Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington, USA.
Papers in Europe PMC - 10Klopstock T5 papers · 2026
Department of Neurology, Friedrich-Baur-Institute, University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany; German Network for mitochondrial disorders (mitoNET), Munich, Germany.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
15
interventional trials for this specific condition
15 interventional trials matched this specific condition name; 4 currently recruiting in our sample.
Data as of 27 July 2026
15 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 93.5th percentile).
low confidence · 93.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
15 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07337551·NOT YET RECRUITING·Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive
Conditions: Patients With Metastatic Colorectal Cancer Who Were TP53-mutant and LRPPRC-positive and Had Previously Failed Prior First-line Treatment·Matched via name phrase
- NCT06970106·RECRUITING·Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle)
Conditions: OPA1 Gene Mutation · Autosomal Dominant Optic Atrophy · Hereditary Optic Atrophies · Kjer Optic Atrophy·Matched via name phrase
- NCT06843811·ENROLLING BY INVITATION·Sirolimus for Leigh Syndrome
Conditions: Leigh Syndrome·Matched via name phrase
- NCT06990984·NOT YET RECRUITING·A Dose-ranging Study of TTI-0102 in Adults and Children With Leigh Syndrome Spectrum (LSS)
Conditions: Leigh Syndrome·Matched via name phrase
Observational and natural-history studies
16 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT01803906·ENROLLING BY INVITATION·Tissue Sample Study for Mitochondrial Disorders
Conditions: Mitochondrial Disorders · Mitochondrial Disease · Melas · Kearns Sayer·Matched via name phrase
- NCT06967831·RECRUITING·Drug Repurposing for Mitochondrial Disorders Using iPSCs Derived Neural Cells
Conditions: Leigh Syndrome (Maternally Inherited, MILS) · Leigh Syndrome (AR, AD, XR)·Matched via name phrase
- NCT01780168·RECRUITING·The NIH MINI Study: Metabolism, Infection, and Immunity in Inborn Errors of Metabolism
Conditions: Oxidative Phosphorylation Deficiencies · Electron Transport Chain Disorders, Mitochondrial · Mitochondrial Disorders · Leigh Disease·Matched via name phrase
- NCT05554835·RECRUITING·Global Registry and Natural History Study for Mitochondrial Disorders
Conditions: Mitochondrial Diseases · Kearns-Sayre Syndrome · MIDD · SANDO·Matched via name phrase
- NCT03137355·RECRUITING·The International Registry for Leigh Syndrome
Conditions: Leigh Syndrome · Leigh Disease · Leigh's Necrotizing Encephalopathy · Subacute Necrotizing Encephalomyopathy·Matched via name phrase
- NCT07038239·RECRUITING·Genotype/Phenotype Correlation of MORC2 Mutations
Conditions: Charcot Marie Tooth Disease · DIFGAN · Developmental Delay (Disorder) · Impaired Growth·Matched via name phrase
- NCT05848271·RECRUITING·Natural History Study of Patients with HPDL Mutations
Conditions: Mitochondrial Encephalomyopathies · Hereditary Spastic Paraplegia · Spastic Paraplegia · White Matter Disease·Matched via name phrase
- NCT07691827·RECRUITING·Maternal Inheritance of a Pathogenic MT-ND1 Mutation Causes Mitochondrial Dysfunction and Spermatogenic Failure in Men
Conditions: Azoospermia, Nonobstructive · Cryptozoospermia·Matched via name phrase
General rare disease registries you may be eligible for
These studies enroll across many rare conditions. They are not counted as evidence that anyone is studying this specific disease.
- NCT01793168·RECRUITING·Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Conditions: Rare Disorders · Undiagnosed Disorders · Disorders of Unknown Prevalence · Cornelia De Lange Syndrome
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Leigh syndrome" OR "Infantile subacute necrotizing encephalopathy" OR "Leigh disease" OR "Leigh syndrome spectrum" OR "Leigh's disease"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Leigh syndrome" OR "Infantile subacute necrotizing encephalopathy" OR "Leigh disease" OR "Leigh syndrome spectrum" OR "Leigh's disease" OR "ADAR" OR "AIFM1" OR "ATP5MK" OR "BCS1L" OR "BTD" OR "CLPB" OR "COQ9" OR "COX10" OR "COX15" OR "COX4I1" OR "COX8A" OR "COXFA4" OR "DLAT" OR "DLD" OR "DNM1L" OR "EARS2" OR "ECHS1" OR "ETHE1" OR "FARS2" OR "FBXL4" OR "FOXRED1" OR "GFM1" OR "GFM2" OR "GTPBP3" OR "HIBCH" OR "HPDL" OR "IARS2" OR "KGD4" OR "LIAS" OR "LIPT1" OR "LONP1" OR "LRPPRC" OR "MECR" OR "MFF" OR "MORC2" OR "MRPS34" OR "MT-ATP6" OR "MT-CO1" OR "MT-CO2" OR "MT-CO3" OR "MT-ND1" OR "MT-ND2" OR "MT-ND3" OR "MT-ND4" OR "MT-ND5" OR "MT-ND6" OR "MT-TI" OR "MT-TK" OR "MT-TL1" OR "MT-TL2" OR "MT-TV" OR "MT-TW" OR "MTFMT" OR "MTRFR" OR "NARS2" OR "NAXE" OR "NDUFA1" OR "NDUFA10" OR "NDUFA12" OR "NDUFA13" OR "NDUFA2" OR "NDUFA3" OR "NDUFA9" OR "NDUFAF2" OR "NDUFAF4" OR "NDUFAF5" OR "NDUFAF6" OR "NDUFAF8" OR "NDUFB8" OR "NDUFC2" OR "NDUFS1" OR "NDUFS2" OR "NDUFS3" OR "NDUFS4" OR "NDUFS7" OR "NDUFS8" OR "NDUFV1" OR "NDUFV2" OR "NUBPL" OR "NUP62" OR "OPA1" OR "PDHA1" OR "PDHB" OR "PDHX" OR "PDSS2" OR "PET100" OR "PET117" OR "PNPT1" OR "POLG" OR "PTCD3" OR "RANBP2" OR "RNASEH1" OR "SCO2" OR "SDHA" OR "SDHAF1" OR "SERAC1" OR "SLC19A3" OR "SLC25A19" OR "SLC25A4" OR "SLC25A46" OR "SLC39A8" OR "SQOR" OR "SSBP1" OR "SUCLA2" OR "SUCLG1" OR "SURF1" OR "TACO1" OR "TARS2" OR "TIMMDC1" OR "TPK1" OR "TRMU" OR "TSFM" OR "TTC19" OR "UQCRQ" OR "VPS13D"
Recall-expansion terms: ADAR, AIFM1, ATP5MK, BCS1L, BTD, CLPB, COQ9, COX10, COX15, COX4I1, COX8A, COXFA4, DLAT, DLD, DNM1L, EARS2, ECHS1, ETHE1, FARS2, FBXL4, FOXRED1, GFM1, GFM2, GTPBP3, HIBCH, HPDL, IARS2, KGD4, LIAS, LIPT1, LONP1, LRPPRC, MECR, MFF, MORC2, MRPS34, MT-ATP6, MT-CO1, MT-CO2, MT-CO3, MT-ND1, MT-ND2, MT-ND3, MT-ND4, MT-ND5, MT-ND6, MT-TI, MT-TK, MT-TL1, MT-TL2, MT-TV, MT-TW, MTFMT, MTRFR, NARS2, NAXE, NDUFA1, NDUFA10, NDUFA12, NDUFA13, NDUFA2, NDUFA3, NDUFA9, NDUFAF2, NDUFAF4, NDUFAF5, NDUFAF6, NDUFAF8, NDUFB8, NDUFC2, NDUFS1, NDUFS2, NDUFS3, NDUFS4, NDUFS7, NDUFS8, NDUFV1, NDUFV2, NUBPL, NUP62, OPA1, PDHA1, PDHB, PDHX, PDSS2, PET100, PET117, PNPT1, POLG, PTCD3, RANBP2, RNASEH1, SCO2, SDHA, SDHAF1, SERAC1, SLC19A3, SLC25A19, SLC25A4, SLC25A46, SLC39A8, SQOR, SSBP1, SUCLA2, SUCLG1, SURF1, TACO1, TARS2, TIMMDC1, TPK1, TRMU, TSFM, TTC19, UQCRQ, VPS13D
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 15 interventional · 16 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase, recall-expansion; with hits: phrase, recall-expansion
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: LS; LSS
Confidence reasoning
- Preferred label is short or not clearly distinctive
- 2 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T14:05:15.981Z
